SKIP TO
CONTENT
Philips Recalled CPAP, Bi-Level PAP, and Mechanical...
featured news
April 18, 2018
SEC Fraud
Anti-Retaliation Whistleblower Protection Under Dodd-Frank
Fifth Court Differentiates Whistleblower Protection If Whistleblower Reports to SEC or Internally to Company The Fifth Circuit ruled on June 17, 2013, that anti-retaliation provisions in Dodd-Frank only protect whistleblowers who disclose alleged fraud to the U.S. Securities and Exchange Commission (“SEC”) and not just internally to the company. The […]
April 18, 2018
Healthcare Fraud
3 Types of Qui Tam Off-Label Marketing Cases
1. Off-Label Marketing vs. Off-Label Prescribing The Food and Drug Administration (“FDA”) requires that drugs be proven to be safe and effective for a particular use before they can be marketed. The FDA’s approval is always limited to use or uses for which the manufacturer has submitted evidence of safety […]
April 18, 2018
Loan Fraud
False Claims Act Liability and Fraudulent Applications for Federally Guaranteed Loans
Is there False Claims Act liability regarding fraudulent applications for federally guaranteed loans where: there are no defaults on those loans after the government guarantees them; the government is not required to expend any funds in support of those guarantees; or the government is otherwise not financially harmed? The question […]
April 18, 2018
SEC Fraud
False Claims Act’s “Alternate Remedy Provision” & The SEC Whistleblower Statute’s “Related Action” Provision
What is the False Claims Act Alternative Remedy Provision? When a relator brings a false claims action in the name of the Government under the False Claims Act (“FCA”), the Government may elect to pursue its claim through any alternate remedy available to the Government, including any administrative proceeding, to determine a civil money […]
April 18, 2018
False Claims Act Information
Indiana False Claims and Whistleblower Protection Act
In 2005, the State of Indiana passed the Indiana False Claims and Whistleblower Protection Act (“Indiana FCA”), its own version of the federal False Claims Act (“FCA”). The Indiana FCA allows private individuals who know about fraud to bring a qui tam case against a person or entity for submitting or causing […]
April 18, 2018
False Claims Act Information
The False Claims Act Public Disclosure Bar and the Meaning of “News Media”
What is Meant by “News Media” Under the False Claims Act? Under the False Claims Act, 31 U.S.C. 3730(e)(4)(A)(iii), “the court shall dismiss an action or claim . . . unless opposed by the government, if substantially the same allegation or transaction as alleged in the action or claims were […]
April 18, 2018
Healthcare Fraud
Anti-Kickback Medicare Part B Fraud Under the Federal False Claims Act
Waiving co-payments and deductibles required under Medicare Part B is a basis for a whistleblower to bring a claim under the federal False Claims Act. About the Medicare Part B Program Title XVIII of the Social Security Act prescribes coverage requirements under Part B of the Medicare program. Medicare Part […]
April 18, 2018
False Claims Act Information
Can a Qui Tam Relator Share in Non-Monetary Proceeds of a False Claims Act Settlement?
The False Claims Act Provides Awards to Successful Whistleblowers The False Claims Act provides for an award to a qui tam plaintiff in the event the government settles a qui tam suit. If the Government settles a qui tam action brought by a whistleblower notifying the government of fraud, the whistleblower (often called a […]
April 18, 2018
False Claims Act Information
Should I Be a Whistleblower and Report Government Fraud?
Why be a Whistleblower? Regardless of your political persuasion, your view about big or small government, or even your position on various government programs, everyone would agree that we need to catch and reduce the amount of fraud committed on the government. Private citizens — whether as consumers, employees, patients […]
April 18, 2018
False Claims Act Legal News
GlaxoSmithKline False Claims Act Suit to Settle for $3 Billion
Pharmaceutical company GlaxoSmithKline has agreed to pay $3 billion in fines to settle criminal and civil violations. The qui tam portion of the civil lawsuit arose under the False Claims Act and is said to be worth over $1 billion. At issue in the civil suit were claims relating to the company’s medications, including […]
February 27, 2018
News
Harold Berger Named to the Academic Life Committee of the School of Engineering and Applied Science of the University of Pennsylvania
Harold Berger was named to the Academic Life Committee of the School of Engineering and Applied Science of the University of Pennsylvania.
February 6, 2018
News
Berger Montague Attorneys Jon Lambiras and Lane Vines Present Securities Fraud Class Action CLE to Association of Certified Fraud Examiners
On February 6, 2018, Berger Montague attorneys Jon Lambiras and Lane Vines presented a 2-hour CLE to the Philadelphia chapter of the Association of Certified Fraud Examiners. It was attended by approximately 60 attorneys, CPAs, and fraud investigators.
schedule a free consultation
"*" indicates required fields
By clicking SUBMIT you agree to our Terms of Use and Privacy Policy and you are providing express consent to receive communications from Berger Montague via calls, emails, and/or text messages.
$50B+
in Settlements & Verdicts
53+
Years of High-Profile Cases
100+
Attorneys Protecting Your Rights
2X
Named “Trial Lawyer of the Year”
50
States in Which The Firm Has Successfully Litigated Cases
On the Cutting Edge of the Profession
Legal Intelligencer
53
Years
